Fig. 9: Humoral protection from IBV challenge is afforded by antibodies that target glycoproteins. | Nature Communications

Fig. 9: Humoral protection from IBV challenge is afforded by antibodies that target glycoproteins.

From: Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

Fig. 9

Mice were vaccinated twice (with a 4-week interval) I.D. with 5 µg of mRNA-LNPs. Sera were collected from vaccinated animals 4 weeks after the boost and then assessed for antibody reactivity towards B/Colorado/06/2017 (V) influenza virus-infected cells (n = 10 mice/group) (a). Sera from vaccinated mice were transferred into naïve mice. Two hours after the transfer, sera from naïve recipients of passive sera were assessed for antibody reactivity towards B/Colorado/06/2017 (V) influenza virus-infected cells (n = 5 mice/group) (b). For a and b bars represent the mean of each group and each point represents an individual animal. Error bars are representative of SD. One mouse was excluded from the NP group due to failed serum transfer. Naïve mice were then I.N. challenged with 5mLD50 of B/New York City/PV01181/2018 (V) influenza virus and weight loss was monitored for 14 days. Data are shown as mean and error bars represent SD (n = 5 per group) (c). The dotted line in c indicates the maximum body weight loss (25%) for the experiment. Source data are provided as a source data file.

Back to article page